As of June 30, 2025, the Company had cash, cash equivalents and marketable securities totaling $138.5 million. Together with net proceeds of approximately $65.1 million from the July 2025 public ...
BALA CYNWYD, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported ...
FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results